| 1 |
33926263 | Effect of PARP Inhibitors as Maintenance Treatment on Restricted Mean Survival Time in Platinum-Sensitive Recurrent Ovarian Cancer: A Systematic Review and Meta-analysis. | 2022 Jan |
3 |
| 2 |
35018214 | Transcriptomics reveals in vivo efficacy of PARP inhibitor combinatorial synergy with platinum-based chemotherapy in human non-small cell lung carcinoma models. | 2022 |
1 |
| 3 |
35124372 | TOPBP1 regulates resistance of gastric cancer to oxaliplatin by promoting transcription of PARP1. | 2022 Mar |
5 |
| 4 |
35219776 | The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer. | 2022 Jun |
2 |
| 5 |
35396812 | A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782). | 2022 Apr 8 |
2 |
| 6 |
33250205 | Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort. | 2021 Jan |
1 |
| 7 |
33423551 | Oregovomab: an investigational agent for the treatment of advanced ovarian cancer. | 2021 Feb |
2 |
| 8 |
33478135 | The Prognostic Relevance of Poly (ADP-Ribose) Polymerase Expression in Ovarian Cancer Tissue of Wild Type and BRCA-Mutation Carrier Patients. | 2021 Jan 19 |
2 |
| 9 |
33515422 | SEOM clinical guideline in ovarian cancer (2020). | 2021 May |
1 |
| 10 |
33617901 | Patient-derived xenograft models of BRCA-associated pancreatic cancers. | 2021 Apr |
1 |
| 11 |
33669671 | Effect of Oxaliplatin, Olaparib and LY294002 in Combination on Triple-Negative Breast Cancer Cells. | 2021 Feb 19 |
1 |
| 12 |
33675937 | The systemic treatment of recurrent ovarian cancer revisited. | 2021 Jun |
2 |
| 13 |
33724122 | Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know. | 2021 May |
1 |
| 14 |
33740262 | Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis. | 2021 Jul 15 |
1 |
| 15 |
33743851 | Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. | 2021 May |
1 |
| 16 |
33882241 | PARP inhibitors and immunotherapy in ovarian and endometrial cancers. | 2021 Dec |
1 |
| 17 |
33920140 | Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway. | 2021 Apr 10 |
1 |
| 18 |
34132814 | Association of T2285C polymorphism in PARP1 gene coding region with its expression, activity and NSCLC risk along with prognosis. | 2021 Aug 27 |
1 |
| 19 |
34520432 | PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancer. | 2021 Nov 1 |
1 |
| 20 |
34593416 | Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm? | 2021 Oct |
2 |
| 21 |
34616492 | Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer. | 2021 |
2 |
| 22 |
34900739 | Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. | 2021 |
1 |
| 23 |
34948122 | New Synthetic Lethality Re-Sensitizing Platinum-Refractory Cancer Cells to Cisplatin In Vitro: The Rationale to Co-Use PARP and ATM Inhibitors. | 2021 Dec 11 |
1 |
| 24 |
34955157 | Mise à jour 2021 des recommandations pour la pratique clinique de Nice/Saint-Paul-de-Vence dans le cancer de l’ovaire épithélial de haut grade: Updated 2021 recommendations for the clinical practice of Nice/Saint-Paul-de-Vence in epithelial high grade ovarian cancer. | 2021 Dec |
1 |
| 25 |
31534014 | ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2-/- Ovarian Cancer Cells. | 2020 Jan |
4 |
| 26 |
31553293 | Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance. | 2020 |
1 |
| 27 |
31594824 | ADP-Ribosylation Levels and Patterns Correlate with Gene Expression and Clinical Outcomes in Ovarian Cancers. | 2020 Jan |
1 |
| 28 |
31650446 | Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach. | 2020 Feb |
1 |
| 29 |
31669203 | PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers. | 2020 Jan 28 |
1 |
| 30 |
31721706 | Anticancer Activity of Platinum (II) Complex with 2-Benzoylpyridine by Induction of DNA Damage, S-Phase Arrest, and Apoptosis. | 2020 |
3 |
| 31 |
31856090 | ATM-Mutated Pancreatic Cancer: Clinical and Molecular Response to Gemcitabine/Nab-Paclitaxel After Genome-Based Therapy Resistance. | 2020 Jan |
1 |
| 32 |
31863638 | Biguanides in combination with olaparib limits tumorigenesis of drug-resistant ovarian cancer cells through inhibition of Snail. | 2020 Feb |
1 |
| 33 |
31902551 | Association of expression of p53, livin, ERCC1, BRCA1 and PARP1 in epithelial ovarian cancer tissue with drug resistance and prognosis. | 2020 Feb |
1 |
| 34 |
32171277 | Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report. | 2020 Mar 14 |
1 |
| 35 |
32172572 | Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. | 2020 Oct |
2 |
| 36 |
32186787 | [PARP INHIBITORS FOR ADJUVANT TREATMENT FOR OVARIAN CANCER]. | 2020 Mar |
2 |
| 37 |
32321768 | Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors. | 2020 Jul |
2 |
| 38 |
32471249 | PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond? | 2020 May 27 |
1 |
| 39 |
32471250 | Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. | 2020 May 27 |
1 |
| 40 |
32512040 | The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer. | 2020 Sep |
1 |
| 41 |
32569725 | The forefront of ovarian cancer therapy: update on PARP inhibitors. | 2020 Sep |
2 |
| 42 |
32575908 | Drugs Targeting Tumor-Initiating Cells Prolong Survival in a Post-Surgery, Post-Chemotherapy Ovarian Cancer Relapse Model. | 2020 Jun 21 |
1 |
| 43 |
32594311 | The Prognostic Value of PARP Expression in High-Grade Epithelial Ovarian Cancer. | 2020 Oct |
1 |
| 44 |
32601814 | Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma. | 2020 Jun 29 |
1 |
| 45 |
32609666 | The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma. | 2020 Mar |
1 |
| 46 |
32612955 | Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer. | 2020 |
1 |
| 47 |
32793315 | Retrospective review of outcomes in patients with DNA-damage repair related pancreatic cancer. | 2020 |
1 |
| 48 |
32817083 | Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis. | 2020 Oct |
4 |
| 49 |
32878963 | DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment. | 2020 Nov |
3 |
| 50 |
32953627 | Secondary and tertiary ovarian cancer recurrence: what is the best management? | 2020 Aug |
2 |